Inventor
JAUTELAT ROLF
DE33 patents
⚠️ This page may combine multiple inventors who share the name “JAUTELAT ROLF”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
Bayer Pharma AG
7 patentsUS9126998B2Sep 8, 2015
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
Bayer Pharma AG17 citations84
US8946215B2Feb 3, 2015
Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
Bayer Pharma AG10 citations84
US8778964B2Jul 15, 2014
Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
Bayer Pharma AG15 citations84
US8796305B2Aug 5, 2014
Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
Bayer Pharma AG14 citations83
US9624214B2Apr 18, 2017
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
Bayer Pharma AG3 citations72
US10662185B2May 26, 2020
Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use
Bayer Pharma AG0 citations51
US10052312B2Aug 21, 2018
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
Bayer Pharma AG0 citations51
SCHERING AG
6 patentsUS7235561B2Jun 26, 2007
Compound and a composition including such a compound
SCHERING AG58 citations95
US7338958B2Mar 4, 2008
Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents
SCHERING AG19 citations92
US7288547B2Oct 30, 2007
CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
SCHERING AG54 citations92
US6844336B2Jan 18, 2005
4-fluoroalkyl-2h-benzopyrans with anti-estogenic activity
SCHERING AG14 citations83
US7456191B2Nov 25, 2008
N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents
SCHERING AG3 citations63
US7018994B2Mar 28, 2006
17α-ALKYL-17β-OXY-ESTRATRIENES AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, USE OF THE 17α-ALKYL-17β-OXY-ESTRATRIENES FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS AS WELL AS PHARMACEUTICAL PREPARATIONS
SCHERING AG3 citations62
BAYER SCHERING PHARMA AG
5 patentsUS7291624B2Nov 6, 2007
CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents
BAYER SCHERING PHARMA AG16 citations92
US7750000B2Jul 6, 2010
Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
BAYER SCHERING PHARMA AG24 citations88
US7598260B2Oct 6, 2009
CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents
BAYER SCHERING PHARMA AG13 citations83
US7943629B2May 17, 2011
Sulphimides as protein kinase inhibitors
BAYER SCHERING PHARMA AG10 citations81
US7538100B2May 26, 2009
17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
BAYER SCHERING PHARMA AG0 citations51
ADVERIO PHARMA GMBH
4 patentsUS9993476B2Jun 12, 2018
Substituted 5-flouro-1H-pyrazolopyridines and their use
ADVERIO PHARMA GMBH16 citations92
US11439642B2Sep 13, 2022
Substituted 5-fluoro-1H-pyrazolopyridines and their use
ADVERIO PHARMA GMBH3 citations84
US10736896B2Aug 11, 2020
Substituted 5-fluoro-1H-pyrazolopyridines and their use
ADVERIO PHARMA GMBH2 citations73
US12064429B2Aug 20, 2024
Substituted 5-fluoro-1H-pyrazolopyridines and their use
ADVERIO PHARMA GMBH0 citations62
FOLLMANN MARKUS
2 patentsBAYER IP GMBH
2 patentsKLAR ULRICH
2 patentsLücking Ulrich
2 patentsUS8802686B2Aug 12, 2014
Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine
Lücking Ulrich4 citations70
US8735412B2May 27, 2014
Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine
Lücking Ulrich6 citations70